Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CellChorus
AddedFeb 16, 2024
UpdatedJul 1, 2026
CellChorus

CellChorus

Seed

CellChorus: AI-driven platform for rapid cell therapy & vaccine development analysis.

HQ
South San Francisco, CA, US
Founded
2017
Accelerator
Y Combinator logoY CombinatorS21
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize cell therapy and vaccine development, CellChorus leverages artificial intelligence to analyze thousands of microscopy videos in parallel. This innovative approach enables the evaluation of immune cell behavior over time, helping customers discover, develop, manufacture, and deliver therapies more efficiently and cost-effectively. Their core product, the TIMING™ platform, quantifies the spatiotemporal performance of individual cells, providing critical insights for top biopharma companies and emerging biotech firms.

Notable figures affiliated with CellChorus include leading scientists and industry experts who contribute to the company's cutting-edge research and development. The company has secured investments from prominent venture capital firms and has achieved significant milestones in accelerating therapeutic development. By enabling a deeper understanding of immune cell performance, CellChorus has made a substantial impact on the biopharma industry, enhancing the success rates of novel therapies and reducing time-to-market.

CellChorus - Similar Companies

Endpoint Health logo

Endpoint Health

Biodock logo

Biodock

biodock.ai

Parallel Bio logo

Parallel Bio

parallel.bio

CellStrat logo

CellStrat

cellstrat.com

Cellarity logo

Cellarity

ImmunoMind logo

ImmunoMind

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Mytos logo

Mytos

mytos.bio

Scaled Biolabs logo

Scaled Biolabs

scaledbiolabs.com

64x Bio logo

64x Bio

64xbio.com

Celldom logo

Celldom

celldom.com

Cellanome logo

Cellanome

cellanome.com

Vibe Bio logo

Vibe Bio

vibebio.com

Scribe Biosciences logo

Scribe Biosciences

Asher Bio logo

Asher Bio

asherbio.com

CellChorus - Quick Facts

Who are CellChorus' competitors?

Companies similar to CellChorus include Endpoint Health, Biodock, Parallel Bio and CellStrat.

When was CellChorus founded?

CellChorus was founded in 2017.

Where is CellChorus' headquarters located?

CellChorus' headquarters is located in South San Francisco, CA, US.

When was CellChorus' last funding round?

CellChorus' most recent funding round was for $2.3M (USD) in June 2023.

How much has CellChorus raised to-date?

As of Jun 21, 2023, CellChorus has raised a total of $2.4M (USD).

How many employees does CellChorus have?

CellChorus has 6 employees as of Feb 5, 2024.

CellChorus - Classification

Ownership
  • Private Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cell Therapy
  • Vaccines
Tags
  • Biotech
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software